KoreaTimes - Bio

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Business

Bio

Thu, March 30, 2023 | 16:55

HLB's US subsidiary promotes efficacy of liver cancer drug Rivoceranib

HLB's US subsidiary promotes efficacy of liver cancer drug Rivoceranib

HLB, a global biopharmaceuticals company, said Thursday that its U.S. subsidiary Elevar Therapeutics announced the efficacy and safety of the Rivoceranib liver cancer drug at a biopharmaceutical symposium in Washington, D.C. This comes as part of the Korean biotech company's efforts to promote the drug ahead of applying for new drug application (NDA) with the U.S. Food and Dr...

Baek Byung-yeul | 2023-03-23 16:24

POSCO International to expand carbon capture biz in green energy push

POSCO International to expand carbon capture biz in green energy push

POSCO International said Tuesday it will nurture carbon capture and storage (CCS) as one of its future growth drivers as the trading company accelerates its expansion into green energy.

2023-03-21 11:32

Samsung Biologics seeks to expand partnerships in New York

Samsung Biologics seeks to expand partnerships in New York

Samsung Biologics will take part in 2023 DCAT Week, a global event in the bio and pharmaceutical industry, which will take place in New York from March 20 to 23, in a bid to seek more partnerships, the company said Thursday. Hosted by the Drug, Chemical & Associated Technologies Association (DCAT), DCAT Week has been a representative networking event in the pharmaceutical ind...

Baek Byung-yeul | 2023-03-16 16:05

Celltrion founder to return to management after 2 year-hiatus

Celltrion founder to return to management after 2 year-hiatus

Seo Jung-jin, founder and honorary chairman of Celltrion, may return to management after two years, on expectations he can save the biotechnology group that is facing growing business uncertainties, according to company officials, Friday.

Baek Byung-yeul | 2023-03-03 16:52

Kakao Healthcare to launch blood sugar managing app in Q3

Kakao Healthcare to launch blood sugar managing app in Q3

Kakao Healthcare, a subsidiary of internet company Kakao, revealed a detailed vision for digital healthcare, saying it will launch a blood sugar management app in the third quarter of this year, according to the CEO, Thursday. “Digital healthcare has emerged as a lucrative business,” Hwang Hee, CEO of Kakao Healthcare, said during a press conference at Kakao's building in Seo...

Baek Byung-yeul | 2023-03-02 16:22

Samsung Biologics hit by series of attempts to steal trade secrets

Samsung Biologics hit by series of attempts to steal trade secrets

Samsung Biologics has been grappling with a series of attempts to steal its trade secrets as competition is intensifying in contract-based drug development and manufacturing, according to police and industry officials, Monday. Incheon Metropolitan Police said one of Samsung Biologics' employees was arrested recently for attempting to take company data from a worksite without ...

Baek Byung-yeul | 2023-02-27 16:56

Will Medytox's legal win over Daewoong deal blow to Hugel?

Will Medytox's legal win over Daewoong deal blow to Hugel?

Medytox's legal win over Daewoong Pharmaceutical is expected to shake up the local botulinum toxin (BTX) market, as Medytox, Korea's first Botox developer, is also embroiled in a legal tussle with another competitor, Hugel in the United States, over the BTX strain used to manufacture the cosmetics treatment, according to the companies, Monday. On Friday, the Seoul District Co...

Baek Byung-yeul | 2023-02-13 16:45

Medytox wins botulinum toxin patent suit against Daewoong

Medytox wins botulinum toxin patent suit against Daewoong

Medytox won a lawsuit against Daewoong Pharmaceutical on Friday over a botulinum toxin (BTX or Botox) patent. The two companies had locked horns over the origin of BTX strain used to manufacture the cosmetic treatment. “Daewoong Pharmaceutical's Nabota was developed by stealing Medytox's botulinum toxin strains and manufacturing process,” the Seoul Central District Court said...

Baek Byung-yeul | 2023-02-12 16:29

HLB's anticancer drug wins approval in China

HLB's anticancer drug wins approval in China

HLB's anticancer drug Rivoceranib was approved to be used for first-line treatment for liver cancer in China, the Korean biotech company said Thursday. The company said China's National Medical Products Administration (NMPA) approved the combination therapy of Rivoceranib and Camrelizumab, an anticancer drug of China's Jiangsu Hengrui Medicine, as a first-line treatment for l...

Baek Byung-yeul | 2023-02-02 16:44

SK Bioscience recruits experts for global expansion

SK Bioscience recruits experts for global expansion

SK Bioscience, developer of SKYCovione, Korea's first COVID-19 vaccine, has recruited renowned executives who have worked for global biopharmaceutical companies as part of its efforts to advance into the global market and diversify, according to the company, Friday. The company said it appointed Richard Kensinger as vice president of R&D project management at its U.S. branch,...

Baek Byung-yeul | 2023-01-20 14:40

1 2 3 4 5 6 7 8

Top 10 Stories

1	Korea to ease entry rules to boost tourism, domestic spending

2	Korea moves to shorten COVID-19 isolation period to 5 days

3	INTERVIEWCan art become stable investment source?

4	Will dismantling oligopoly result in successful bank industry reform?

5	Generation Z entrepreneurs turn oyster shells into trendy dish soap

6	Celltrion chairman vows to develop new drugs, initiate M&As

7	Terraform Labs co-founder's extradition could be delayed more than 1 month

8	Fintech, lifestyle products can help Korea grow trade ties with Hong Kong: city's trade promotion chief in Korea

9	Ex-journalist to lead NK defector support foundation

10	Top envoy to US tapped as new national security advisor

DARKROOM